BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

August 26, 2020

SAN CARLOS, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

Webcast link:

In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020.  To schedule a meeting please contact Eric Lahiji at

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit

Media Contact:
Michelle McAdam, Chronic Communications, Inc.
(310) 902-1274 

Investor Contact:
David McClung, Chief Financial Officer
(650) 226-0120


Have questions?
: (800) 624-1179
Have questions?

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.